Distinguished in Gout

Dr. Prashanth R. Sunkureddi

Prashanth R. Sunkureddi, M.D., P.A.
League City, TX
Distinguished
in Gout
Specialties:Rheumatology
OverviewInsuranceLocationsClinical Research

Overview

Prashanth Sunkureddi is a Rheumatologist in League City, Texas. Dr. Sunkureddi and is rated as a Distinguished provider by MediFind in the treatment of Gout. His top areas of expertise are Arthritis, Gout, Rheumatoid Arthritis (RA), and Psoriatic Arthritis.

His clinical research consists of co-authoring 7 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Gout.

Specialties
Rheumatology
Licenses
Internal Medicine in TX
Hospital Affiliations
Houston Methodist Clear Lake Hospital
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Blue Cross Blue Shield
  •  Humana

Locations

PRASHANTH R. SUNKUREDDI, M.D., P.A.
3725 E League City Pkwy, Suite 200, League City, TX 77573
281-957-9127

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 104-Week Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE)
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 104-Week Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Completed
Publish Date: February 18, 2025
Intervention Type: Drug
Study Drugs: Rituximab, Standard therapy (Including Immunosuppressants), Standard therapy (Excluding Immunosuppressants), Steroid Taper
Study Phase: Phase 3
A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
Enrollment Status: Active_not_recruiting
Publish Date: January 22, 2025
Intervention Type: Drug
Study Drugs: Baricitinib, TNF Inhibitor
Study Phase: Phase 4
A 5-Year Prospective Observational Registry to Assess Adverse Events of Interest and Effectiveness in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Treated With or Without BENLYSTA™ (Belimumab)
A 5-Year Prospective Observational Registry to Assess Adverse Events of Interest and Effectiveness in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Treated With or Without BENLYSTA™ (Belimumab)
Enrollment Status: Active_not_recruiting
Publish Date: January 20, 2025
Intervention Type: Other, Biological
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: October 12, 2023
Intervention Type: Drug
Study Drugs: Olokizumab, Methotrexate
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Drug: Olokizumab
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: November 23, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, 2-Part Phase 2 Study to Evaluate the Safety and Efficacy of LY3337641 in Adult Subjects With Rheumatoid Arthritis: The RAjuvenate Study
A Randomized, Double-Blind, Placebo-Controlled, 2-Part Phase 2 Study to Evaluate the Safety and Efficacy of LY3337641 in Adult Subjects With Rheumatoid Arthritis: The RAjuvenate Study
Enrollment Status: Terminated
Publish Date: October 09, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

7 Total Publications

Characterization of Patients with Ankylosing Spondylitis Receiving Secukinumab and Reasons for Initiating Treatment: A US Physician Survey and Retrospective Medical Chart Review.
Characterization of Patients with Ankylosing Spondylitis Receiving Secukinumab and Reasons for Initiating Treatment: A US Physician Survey and Retrospective Medical Chart Review.
Journal: Drugs - real world outcomes
Published: January 09, 2019
Similar Doctors
Expertise in
15
conditions
Dr. Vijaya L. Murthy
Rheumatology
Expertise in
15
conditions
Dr. Vijaya L. Murthy
Rheumatology

Utmb Faculty Group Practice

301 University Blvd, 
Galveston, TX 
 (20.6 mi)
409-772-2222
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Vijaya Murthy is a Rheumatologist in Galveston, Texas. Dr. Murthy and is rated as an Advanced provider by MediFind in the treatment of Gout. Her top areas of expertise are Rheumatoid Arthritis (RA), Rhizomelic Pseudopolyarthritis, Gout, and Lupus Nephritis. Dr. Murthy is currently accepting new patients.

Expertise in
10
conditions
Dr. Emilio B. Gonzalez
Rheumatology
Expertise in
10
conditions
Dr. Emilio B. Gonzalez
Rheumatology
301 University Blvd, 
Galveston, TX 
 (20.6 mi)
409-772-2222
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Emilio Gonzalez is a Rheumatologist in Galveston, Texas. Dr. Gonzalez and is rated as an Advanced provider by MediFind in the treatment of Gout. His top areas of expertise are MASS Phenotype, Mixed Connective Tissue Disease, Rheumatoid Arthritis (RA), and Adult Still's Disease. Dr. Gonzalez is currently accepting new patients.

Expertise in
4
conditions
Dr. Jasvinder Singh
Rheumatology
Expertise in
4
conditions
Dr. Jasvinder Singh
Rheumatology

Baylor College Of Medicine

7200 Cambridge St, Fl 10, 
Houston, TX 
 (25.5 mi)
713-798-1000
Languages Spoken:
English, Hindi, Punjabi
See accepted insurances
Accepting New Patients

Jasvinder Singh is a Rheumatologist in Houston, Texas. Dr. Singh and is rated as an Advanced provider by MediFind in the treatment of Gout. His top areas of expertise are Gout, Mixed Connective Tissue Disease, MASS Phenotype, and Bursitis. Dr. Singh is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile